A Phase I/II Evaluation of Stavudine (d4T) in Children With Human Immunodeficiency Virus InfectionMark W. Kline, William T. Shearer, Lin Woods et al.|PEDIATRICS|1995Cited by 79
Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5Robert A. Ogert, John A. Howe, Robert Ralston et al.|Virology|2010Cited by 40
Combination Therapy With Stavudine and Didanosine in Children With Advanced Human Immunodeficiency Virus Infection: Pharmacokinetic Properties, Safety, and Immunologic and Virologic EffectsMark W. Kline, Lisa M. Dunkle, Courtney V. Fletcher et al.|PEDIATRICS|1996Cited by 31
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in AdultsDeborah Theodore, William Smith, Angela R Branche et al.|JAMA Network Open|2023Cited by 23
Determination of Dosing Guidelines for Stavudine (2′,3′-Didehydro-3′-Deoxythymidine) in Children with Human Immunodeficiency Virus InfectionSanjeev Kaul, Lisa M. Dunkle, Mark W. Kline et al.|Antimicrobial Agents and Chemotherapy|2001Cited by 16